We are collaborating with Foundation Medicine to deliver genomic profiling to patients in our lunresertib clinical trials and beyond. We are thrilled to take this next step with the global leader in companion diagnostic approvals for next generation sequencing testing, with the potential to develop a companion diagnostic and expand access to clinical trial sites for our global lunresertib program. Learn more here: https://lnkd.in/enRH_8eA #precisiononcology #clinicaltrials #companiondiagnostic #PKMYT1inhibition
Repare Therapeutics’ Post
More Relevant Posts
-
attending Esmo, visit this poster to see real implementation of the most comprehensive genomic panel #CGP with better results than TSO500, easy process, and a failure rate less than 5% in routine
Assistant Professor & Precision Medicine Consultant | Translating molecular diagnostics and cancer genomics into healthcare
Day #3 of #ESMO23 in Madrid 🇪🇦: Please stop by poster 1253P if you are interested in #PrecisionOncology. Happy to discuss the capabilities of comprehensive genomic profiling and our implementation of OncoDNA OncoDEEP for precision diagnostics (HRD, TMB, MSI etc.) in clinical routine.
To view or add a comment, sign in
-
Ahead of the curve…
With over 20 pieces of research, we’re excited to share new data around the emerging applications of our liquid biopsy & monitoring portfolio, as well as studies investigating new biomarkers and the expanding utility of comprehensive genomic profiling, including Foundation Medicine’s new RNA test. Click the link to learn more about everything we’re presenting at #ASCO24: https://bit.ly/3WNlYdJ
Foundation Medicine at 2024 ASCO® Annual Meeting
To view or add a comment, sign in
-
Innovative Leader | Connector | Motivator | People Focused | Problem Solver Extraordinaire | Product Launch Wizard | 21 years of striving for excellence
Our data at ASCO this year highlights the important role genomic profiling plays in cancer care and research and can be grouped into four major buckets: - Emerging Applications of Liquid Biopsy Using FoundationOne®Liquid CDx and FoundationOne®Tracker. - Utility of CGP in Earlier Stages of Disease, Rare Cancers, and Using RNA Sequencing. - New CGP Biomarkers, Including Homologous Recombination Deficiency (HRD) Signature and Methyl Thioadenosine Phosphorylase (MTAP) Genomic Loss. - Impact of Ancestry on the Genomic Alteration Landscape.
With over 20 pieces of research, we’re excited to share new data around the emerging applications of our liquid biopsy & monitoring portfolio, as well as studies investigating new biomarkers and the expanding utility of comprehensive genomic profiling, including Foundation Medicine’s new RNA test. Click the link to learn more about everything we’re presenting at #ASCO24: https://bit.ly/3WNlYdJ
Foundation Medicine at 2024 ASCO® Annual Meeting
To view or add a comment, sign in
-
Global Scientific Director Integrated Healthcare Solutions, Personalized Medicine Oncology chez Roche
Great research and evidence to continuously improve patient care.
With over 20 pieces of research, we’re excited to share new data around the emerging applications of our liquid biopsy & monitoring portfolio, as well as studies investigating new biomarkers and the expanding utility of comprehensive genomic profiling, including Foundation Medicine’s new RNA test. Click the link to learn more about everything we’re presenting at #ASCO24: https://bit.ly/3WNlYdJ
Foundation Medicine at 2024 ASCO® Annual Meeting
To view or add a comment, sign in
-
🎥 2 Days Left! Transforming Clinical Diagnostics DNBSEQ-T7: Your gateway to Whole Genome Sequencing We're counting down the days until our transformative webinar. We will examine the integration of WGS into clinical practice, discussing specific cases and studies where WGS has aided clinical decisions. Key topics will include the detection of rare and complex mutations, the identification of actionable targets for therapy, and the role of WGS in identifying genomic signatures. Don’t miss out, register now and join us on April 24th to see how you can leverage WGS to revolutionize clinical diagnostics. Click to register: https://lnkd.in/evnFN5c9 #WholeGenomeSequencing #Sequencing #clinical MGI
To view or add a comment, sign in
-
-
Facing challenges to keep up with emerging predictive biomarkers such as TMB? Read how PGDx elio™ tissue complete is empowering laboratories to deliver comprehensive tumor profiling in our new case study. Download our new case study.
To view or add a comment, sign in
-
Central Laboratory Services | Non-Clinical | Clinical Phase I-IV | Preclinical | Early Development | Biomarkers | Business Development | Inside Sales
Facing challenges to keep up with emerging predictive biomarkers such as TMB? Read how PGDx elio™ tissue complete is empowering laboratories to deliver comprehensive tumor profiling in our new case study. Download our new case study.
Adopting a comprehensive genomic profiling (CGP) solution that meets the ordering oncologists’ needs.
learn-more.com
To view or add a comment, sign in
-
Implementing comprehensive rapid genomic testing into your diagnostic evaluation can return results—and help you better address your patients’ unique needs—in as little as 5 days. For acutely and critically ill babies, using rapid whole genome sequencing (rWGS) as a first-tier test can influence clinical management, reduce overall healthcare costs, and prevent a diagnostic odyssey. #NICUAwareness #NICUAwarenessMonth #NICUWarriors #NICU #GenomicSequencing #GenomeSequencing #GeneticTesting
To view or add a comment, sign in
-
-
Great to see this story in (pre)print from Bing Wu, Spyros Darmanis, Zora Modrusan, and many other former colleagues from Genentech! Here, they describe their inexpensive and super high-throughput single cell sequencing method called "Overloading And unpacKing" (OAK). Useful for many applications, including lineage tracing (which they demonstrate) and various functional genomics approaches. #singlecell #crispr #genomics #genomesequencing https://lnkd.in/exDecn4C
Overloading And unpacKing (OAK) - droplet-based combinatorial indexing for ultra-high throughput single-cell multiomic profiling
biorxiv.org
To view or add a comment, sign in
-
Associate Director, Proposal Management at Labcorp | Early Development | Enterprise Client Solutions
Facing challenges to keep up with emerging predictive biomarkers such as TMB? Read how PGDx elio™ tissue complete is empowering laboratories to deliver comprehensive tumor profiling in our new case study. Download our new case study.
Adopting a comprehensive genomic profiling (CGP) solution that meets the ordering oncologists’ needs.
learn-more.com
To view or add a comment, sign in
Healthcare Commercialization Partner for Biotech, Biopharma, Med Device & Med Tech
2moThis sounds like a great collaboration!